Inoperable HCC patients receiving SIR-Spheres® treatment in the SARAH (467 patients) and the SIRveNIB (360 patients) studies had
- no significant improvement in overall survival (primary endpoint not met) 1,2
- significantly better-tolerated treatment1,2
- significantly reduced frequency and severity of side effects1,2
- significantly better Quality of Life1
- significantly improved PFS and TTP in the SIRveNIB study (overall and in the liver; treated population)2
1 Vilgrain V et al. Lancet Oncol 2017; 18: 1624–36.
2 Chow PKH et al. J Clin Oncol 2017; 35 (Suppl): Abs 4002.